Telotristat Etiprate Appears to Halt Carcinoid Heart Disease

#1272

Introduction: Carcinoid Heart Disease (CHD) is a serious complication of the Carcinoid Syndrome (in as many as 50% of patients during the course of their disease). 46% of cases operated with bioprosthetic valves develop recurrent carcinoid valvulopathy on the newly implanted tissue valves. Until now, only mechanical prosthetic valves avoid recurrent fibrosis.

Aim(s): To demonstrate the effects of telotristat etiprate, a tryptophan hydroxylase inhibitor, on serotonin levels and its effect upon the course of CHD.

Materials and methods: 2 patients with CHD were among those entered in the TELESTAR phase III trial. One demonstrated recurrent carcinoid valve disease on the tricuspid and pulmonic bioprosthetic (tissue) replaced valves; the other demonstrated carcinoid valve disease on the native tricuspid and pulmonic valves, suggesting the likelihood that valve surgery might be imminent.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Zacks J

Authors: Zacks J, Lavine R, Ratner L, Warner R,

Keywords: carcinoid heart disease, valve, heart failure, carcinoid syndrome, prosthetic valves, telotristat etiprate,